Heather Losey

Heather Losey

Company: Alkermes

Job title: Senior Director, Research Program Lead, Oncology


Emerging clinical data with nemvaleukin alfa, a novel, engineered cytokine as monotherapy and in combination with pembrolizumab in multiple tumor types 1:30 pm

Overview of nemvaleukin’s design and mechanism of action via targeting the intermediate-affinity IL-2 receptor Deep dive into our melanoma and RCC monotherapy clinical activity and next steps Ovarian data in combination with pembrolizumab and how we are pursuing these clinical signals in a systematic wayRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.